Mainboard · BSE and NSEDraft filed

Integris Medtech Limited IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: Addendum dated Mon 19 Oct 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
Not announced
Fresh issue
₹925.00 crore
DRHP dated Thu 9 Oct 2025, page 1
Offer for sale
2,16,74,531 shares (Amount not stated in the draft)
DRHP dated Thu 9 Oct 2025, page 1
Bid dates
Not announced
Listing date
Not announced
Risk factors
91
DRHP dated Thu 9 Oct 2025, page 84
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedWed 15 Oct 2025 confirmedDRHP dated Thu 9 Oct 2025
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:₹696.39 crore
General corporate purposesNot stated in the draft
TotalNot stated in the draft

The offer for sale goes to the selling shareholders, not the company. DRHP dated Thu 9 Oct 2025, page 122

Company and promoters

As described in the DRHP

This portfolio includes cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. We operate manufacturing facilities in India, Germany, and the Netherlands, and work with global manufacturers supporting a portfolio of medical devices and laboratory solutions sold in more than 65 countries, as of June 30, 2025.

DRHP dated Thu 9 Oct 2025, page 21

Promoters

  • Evercure Holdings Pte. Ltd.
  • Medicore Holdings Pte. Ltd.
  • 2 individual promoters

DRHP dated Thu 9 Oct 2025, page 21

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group84.04%Not stated in the DRHP
Public15.96%Not stated in the DRHP

DRHP dated Thu 9 Oct 2025, page 115

Financials (restated)

Itemthree months period ended June 30, 2025Financial Year ended March 31, 2025Financial Year ended March 31, 2024Financial Year ended March 31, 2023
Revenue from operations₹485.25 crore₹1,902.47 crore₹1,553.38 crore₹1,348.10 crore
Profit after tax₹267.57 crore₹70.68 crore-₹4.88 crore-₹40.54 crore
Net worth₹3,889.99 crore₹2,752.52 crore₹2,681.02 crore₹2,629.52 crore
Total borrowings₹793.42 crore₹1,729.46 crore₹813.10 crore₹556.54 crore

DRHP dated Thu 9 Oct 2025, page 23

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Evercure Holdings Pte. Ltd.Company1,51,74,251Not announced
Individual shareholderIndividual32,50,140Not announced
Individual shareholderIndividual32,50,140Not announced
Total offer for saleNot stated in the draft

DRHP dated Thu 9 Oct 2025, page 1

Peer comparison (as in the DRHP)

ParticularsStandalone/ ConsolidatedFace value per equity share (₹)Closing Price as on October 8, 2025 (₹)P/ERevenue from operations for fiscal 2025 (₹ in million)EPS (Basic) (₹)EPS (Diluted) (₹)RoNW (%)Net Asset Value per Equity Share (₹)
Our Company**Consolidated1NANA***19,024.665.825.731.84316.09
Poly Medicure LimitedConsolidated51,911.0056.0216,698.3234.1334.1112.26278.46
Laxmi Dental LimitedConsolidated2326.4053.952,391.076.076.0516.0937.71

Reproduced from the DRHP dated Thu 9 Oct 2025, page 168; InsightPier adds no figures

Risk factors

91 total
  1. The company had losses in Fiscal 2024 and Fiscal 2023, and its profit for the June 2025 quarter came mainly from a one-time accounting gain (DRHP page 39)
  2. Most revenue comes from outside India, which exposes the company to overseas economic, regulatory and operational risks (DRHP page 40)
  3. Growth has depended on acquisitions, and future deals may be hard to integrate or may not deliver the expected value (DRHP page 41)
  4. Delays or failures in getting or renewing regulatory approvals in India or abroad could stop the company selling its products (DRHP page 42)
  5. Product quality issues, recalls or safety alerts on its medical devices could disrupt operations and cause losses (DRHP page 43)

All 91 risk factors, DRHP pages 39 to 84

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts